WVE·Nasdaq·US
Wave Life Sciences
Wave Life Sciences is a clinical-stage biotechnology company developing RNA medicines (oligonucleotides) using its PRISM platform, which combines chemistry innovation, stereopure oligonucleotide design and human genetics to target RNA for treating rare and common diseases. Its pipeline includes programs in obesity, alpha-1 antitrypsin deficiency, PNPLA3 I148M liver disease, Duchenne muscular dystrophy and Huntington's disease, along with preclinical programs and a collaboration with GSK.
Source: SEC 10-K Feb 26, 2026
Recent Activity
Updated Sep 24, 2026
–Wave Life Sciences appointed Dr. Monika Vnuk as its new Chief Business Officer.
Past updates are part of the Pro plan.
Thematic Position
Relationship Groups
Relationship details are part of the Pro plan.